UK Cannabis Survey: Hope for Mental Health, Data Questions Arise

LONDON – May 22, 2026 – A landmark survey from a consortium of the UK's largest private medical cannabis clinics has delivered striking results, suggesting that an overwhelming majority of patients prescribed the treatment for mental health conditions report significant improvements in their symptoms and overall quality of life. The findings offer a powerful message of hope for those with treatment-resistant conditions but also reignite a fierce debate within the medical community about the quality of evidence and the future of cannabis in mainstream healthcare.

The collaborative report, released by Mamedica, Alternaleaf, CB1 Medical, and Curaleaf, details findings from over 6,000 patients. A specific analysis of 5,128 patients receiving treatment for anxiety, depression, or post-traumatic stress disorder (PTSD) found that 97.6% reported an improvement in their symptoms. The data paints a picture of profound life changes: 93.5% noted an improved ability to function day-to-day, and 92.3% experienced better sleep.

Perhaps most compellingly, 90.7% of these patients described medical cannabis as more effective than previous treatments they had tried, with 88.3% calling it the most effective treatment they have ever used. These figures are particularly poignant given the context of the UK’s strained mental health services, where more than four million people were in contact with NHS services in 2024/25, and many face long waits for care or find conventional treatments inadequate.

A New Frontier in Mental Healthcare?

The survey's results land at a critical moment for mental healthcare in the United Kingdom. Published analyses from major studies like the STAR*D trial have previously suggested that around a third of patients with major depression fail to find relief even after trying multiple established treatments. For this population, who often live with debilitating symptoms for years, the survey’s findings represent more than just statistics; they represent a potential lifeline.

Patients turning to private clinics for medical cannabis are typically required to have already exhausted conventional options available on the NHS. The high satisfaction rates reported in the survey suggest that for this specific group of treatment-resistant individuals, cannabis-based medicines are filling a crucial therapeutic gap. The reported improvements in sleep and daily functioning are particularly significant, as these are often the first casualties of chronic mental health conditions and are fundamental to overall well-being and recovery.

The consortium’s data adds a substantial new dataset to a growing collection of real-world evidence. However, the clinics themselves are careful to manage expectations, noting in their press release that these cross-sectional findings should not be interpreted as definitive evidence of efficacy. Instead, they position the survey as a vital contribution to a broader understanding of patient experience, one that warrants further and more rigorous scientific investigation.

The Evidence Dilemma: Real-World Data vs. Clinical Rigour

Despite the overwhelmingly positive patient reports, the survey immediately runs into the central dilemma of medical cannabis research: the gap between real-world experience and the gold standard of clinical evidence. Sceptics and regulatory bodies point to the survey's methodological limitations. As a voluntary, self-reported, and cross-sectional study, it is susceptible to several forms of bias.

Patients who have had a positive experience may be more motivated to complete a survey than those who found the treatment ineffective or experienced negative side effects, potentially skewing the results. Furthermore, without a placebo or control group, it is scientifically impossible to prove that the cannabis itself caused the improvements, as opposed to the placebo effect or other lifestyle changes.

This cautious stance is reflected in the positions of major medical bodies. The Royal College of Psychiatrists, for instance, maintains that there is currently insufficient high-quality evidence from randomised controlled trials (RCTs) to recommend medical cannabis for most psychiatric conditions. Similarly, the National Institute for Health and Care Excellence (NICE) has not recommended its use for anxiety or depression on the NHS, citing a lack of robust data. These organisations prioritise large-scale, placebo-controlled trials, which are expensive and complex to run but are considered the only definitive way to prove a treatment's safety and efficacy.

This leaves patients, doctors, and policymakers at an impasse. On one hand, thousands of patients are reporting life-changing benefits. On the other, the medical establishment demands a level of proof that does not yet exist for most conditions, creating a significant barrier to wider acceptance and accessibility, particularly within the NHS.

The Private Path to Access

The survey inadvertently highlights the two-tier system that has emerged in the UK since medical cannabis was legalised in 2018. While legally available, cannabis-based medicines for mental health are almost never prescribed on the NHS. This has forced desperate patients into the private sector, where access is determined not just by clinical need, but by the ability to pay.

Private clinics like those in the consortium operate within a strict legal framework, regulated by the Care Quality Commission (CQC) and staffed by doctors on the GMC Specialist Register. They provide a legitimate and regulated pathway for patients, but it comes at a significant cost. Monthly expenses for medication and consultations can run into hundreds of pounds, creating a prohibitive financial barrier for many.

Beyond the cost, patients face lingering stigma and logistical hurdles. They must prove they have failed on at least two conventional treatments before being considered, a process that can take years. This reality contrasts sharply with the celebratory tone of the survey's findings, underscoring the difficult journey many must undertake to achieve the relief reported. Patient advocacy groups like PLEA (Patient-Led Engagement for Access) have long campaigned against these inequalities, arguing that a treatment deemed effective by so many should not be accessible only to the wealthy.

This survey, by pooling data from multiple clinics for the first time, marks a significant step in the industry's effort to build a more formal evidence base. It adds to existing UK real-world data from initiatives like Drug Science’s Project Twenty21 and the UK Medical Cannabis Registry, which have reported similarly positive outcomes. By committing to repeating the survey annually, the consortium signals an intent to move beyond anecdotal success stories and contribute to the long-term data collection that regulators and clinicians demand. Whether this real-world evidence can eventually bridge the gap with clinical science and influence national policy remains the critical question for the future of mental healthcare in the UK.